The FDA accepted two therapies using CAR-T cells: axicabtagene ciloleucel and tisagenlecleucel, which targeted CD19 in 2017 in order to treat Hodgkin’s B cell lymphoma (HGBCL) and relapsed acute lymphoblastic leukemia (ALL), respectively. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.